Ratings by UBS (Priya Sachdeva)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/26/2026 | Penumbra | PEN | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/16/2026 | Penumbra | PEN | Downgrade | Neutral (Buy) |
350.49 (338.64) |
-3.38% | Details | |
| 1/14/2026 | NeuroPace Inc | NPCE | Maintain | Buy (Buy) |
|
Details | ||
| 12/16/2025 | NeuroPace Inc | NPCE | Maintain | Buy (Buy) |
|
Details | ||
| 12/9/2025 | NeuroPace Inc | NPCE | Maintain | Buy (Buy) |
|
Details | ||
| 7/30/2025 | Penumbra | PEN | Maintain | Buy (Buy) |
|
Details | ||
| 6/12/2025 | NeuroPace Inc | NPCE | Maintain | Buy (Buy) |
|
Details | ||
| 4/24/2025 | Penumbra | PEN | Maintain | Buy (Buy) |
|
Details | ||
| 2/19/2025 | Penumbra | PEN | Maintain | Buy (Buy) |
|
Details | ||
| 1/21/2025 | NeuroPace Inc | NPCE | New Coverage | Buy (N/A) |
11.91 (14.03) |
17.8% | Details | |
| 1/21/2025 | Penumbra | PEN | New Coverage | Buy (N/A) |
262.31 (350.49) |
33.62% | Details |
